‘Ignore our drug prices’, Greece tells Europe
This article was originally published in Scrip
National pricing and reimbursement authorities in Europe should not use Greek medicine prices to set their own prices, the Greek health ministry has said on its website.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.